ArticleJournal of diabetes research2026
Integrative Investigation of Lactylome-Proteome Interplay in Diabetic Cardiomyopathy for Pinpointing Disease Development-Associated Pathways or Proteins.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimLysine lactylation (Kla) has emerged as a novel posttranslational modification implicated in various disease processes, yet its role in diabetic cardiomyopathy (DCM) pathogenesis remains unknown. The objective of this study was to ascertain whether protein lactylation is involved in DCM progression.
methodsProteomic and lactate analysis via liquid chromatography with tandem mass spectrometry was performed on the heart tissues of db/m mice (as the control group) and db/db mice (as the DCM group). Subsequently, a series of bioinformatics analyses was employed to analyze the Kla site and Kla-modified proteins in the two groups.
resultsBioinformatics analysis revealed a greater abundance of Kla sites in the DCM group than in the control group. In addition, subcellular localization analysis indicated that Kla-modified proteins were predominantly located in the cytoplasm and mitochondria. Protein lactylation modification mainly occurred on histone H2, and in comparison to the control group, modification of the H4C1-K32 site was notably elevated in the DCM group. Furthermore, 113 significantly modified Kla sites were associated with 78 modified proteins in the DCM group, whereas 37 significantly modified Kla sites were associated with 25 modified proteins in the control group. These Kla-modified proteins participated in biological processes and pathways related to glucose metabolism and DCM. Finally, five candidate sites were identified using random forest, LASSO regression, support vector machine-recursive feature elimination, and logistic regression: A2ASS6_K928_Ttn, A2ASS6_K13499_Ttn, Q61425_K212_Hadh, Q8K2B3_K517_Sdha, and Q9R0Y5_K100_Ak1.
conclusionsOur findings suggest that protein lactate modification in the lactylome and proteome could be a promising treatment for DCM. This provides a reliable basis for further investigating the roles of Kla and Kla-modified proteins to develop new and effective therapeutic targets for treating DCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.